Skip to content
Screener

Stoke Therapeutics, Inc. STOK Total Non-Current Liabilities

Total Non-Current Liabilities at other companies

Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$144.14M-9.9%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$2.06B+187%
Enterprise value$1.91B+206%
P/S64.2×+60.6×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0×0.0×
Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.

The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211874
Line itemMarch 31, 2026December 31, 2025
Total current liabilities$40,806$57,875
Deferred revenue - net of current portion6,6036,961
Other long-term liabilities9911,141
Total long-term liabilities7,5948,102
Total liabilities$48,400$65,977
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,240,347 and 58,921,999 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively65

Item 1. Financial Statements.

FAQ

What is Stoke Therapeutics, Inc.'s total non-current liabilities?
Stoke Therapeutics, Inc. (STOK) reported total non-current liabilities of $7.59M in Q1 2026.
How has Stoke Therapeutics, Inc.'s total non-current liabilities changed year-over-year?
Stoke Therapeutics, Inc.'s total non-current liabilities decreased by 37.4% year-over-year, from $12.13M to $7.59M.
What is the long-term trend for Stoke Therapeutics, Inc.'s total non-current liabilities?
Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s total non-current liabilities has grown at a 80.6% compound annual growth rate (CAGR), from $422K to $8.1M.
What does total non-current liabilities mean?
The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.

Ask your AI about Stoke Therapeutics, Inc.'s total non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude